Childhood lymphoma.
Treatment for childhood lymphoma has been optimized over the last 20 years. The overall survival rate now exceeds 80%. Recently, novel treatment strategies including antibodies and/or targeted therapies are expected to hold promise for advancing outcomes in children with refractory and/or relapsed lymphoma. It is also a currently important challenge to reduce the long-term toxicities associated with contemporary treatments. This review outlines the epidemiology, etiology, clinical presentation, diagnosis, and treatment of childhood lymphoma. In addition, some of the current clinical trials for childhood lymphoma being conducted in Japan are introduced.